Market research
0K9A.F FSD Pharma Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 47M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.18
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA35954B2066
- Market cap
- 47M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.18
About
About FSD Pharma Inc
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0K9A.F discussion.
5 years, 5 months ago
FSD Pharma Inc is currently in a long term downtrend where the price is trading 14.2% below its 200 day moving average.
From a valuation standpoint, the stock is 93.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 80.8.
FSD Pharma Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 75.7% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 9.2% to $-4M since the same quarter in the previous year.
Based on the above factors, FSD Pharma Inc gets an overall score of 3/5.